Table 2.
Clinical characteristics of FMF patients with long-term remission
| Variable |
Remission group1 |
Control |
P value |
|---|---|---|---|
| N = 33 | N = 33 | ||
|
FMF attacks (%) |
|
|
|
| Peritonitis |
81.8 |
97.0 |
.052 |
| Arthritis |
24.2 |
48.5 |
.036 |
| ELE |
12.1 |
39.4 |
.011 |
| Pleuritis |
21.2 |
51.5 |
.010 |
|
Non-attack manifestations (%) |
|
|
|
| Exertional leg-pain |
18.2 |
42.4 |
.030 |
| Splenomegaly |
15.2 |
12.1 |
.500 |
| Anemia |
3.0 |
18.2 |
.052 |
| Proteinuria or amyloidosis
2
|
0 |
3.0 |
.500 |
| Renal failure |
0 |
6.1 |
.246 |
| Dialysis |
0 |
3.0 |
.500 |
|
Treatment (%) |
|
|
|
| Good response to colchicine
3
|
100.0 |
87.9 |
.057 |
| Colchicine dose ≥ 2 mg/day
4
|
9.1 |
51.5 |
<.001 |
|
Severity score (%) |
|
|
|
| Mild |
69.7 |
33.3 |
.003 |
| Moderate or severe |
30.3 |
66.7 |
|
| Elevated APRs (%) | 0 | 30 |
ELE Erysipelas like erythema. APRs Acute phase reactants (ESR or CRP). 1Over the entire course of their disease. 2Biopsy proven.3Defined as less than one attack per month while on colchicine treatment.4Adjusted according to patient’s response.